# A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

> **NCT05771883** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 102 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** IMM0306
- **DRUG:** Lenalidomide capsule

## Key facts

- **NCT ID:** NCT05771883
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05
- **Primary completion:** 2025-05
- **Final completion:** 2025-11
- **Target enrollment:** 102 (ESTIMATED)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05771883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05771883, "A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05771883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*